JP5016778B2 - ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド - Google Patents

ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド Download PDF

Info

Publication number
JP5016778B2
JP5016778B2 JP2002529162A JP2002529162A JP5016778B2 JP 5016778 B2 JP5016778 B2 JP 5016778B2 JP 2002529162 A JP2002529162 A JP 2002529162A JP 2002529162 A JP2002529162 A JP 2002529162A JP 5016778 B2 JP5016778 B2 JP 5016778B2
Authority
JP
Japan
Prior art keywords
methyl
glucopyranosyl
tri
sulfonate
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002529162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509902A (ja
JP2004509902A5 (cg-RX-API-DMAC7.html
Inventor
デュチョソワ，フィリップ
エルベール，ジャン−マルク
ペティトゥ，モリス
サヴィ，ピエール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2004509902A publication Critical patent/JP2004509902A/ja
Publication of JP2004509902A5 publication Critical patent/JP2004509902A5/ja
Application granted granted Critical
Publication of JP5016778B2 publication Critical patent/JP5016778B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2002529162A 2000-09-22 2001-09-20 ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド Expired - Fee Related JP5016778B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR00/12094 2000-09-22
FR0012094A FR2814463B1 (fr) 2000-09-22 2000-09-22 Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
PCT/FR2001/002918 WO2002024754A1 (fr) 2000-09-22 2001-09-20 Polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012027377A Division JP2012131809A (ja) 2000-09-22 2012-02-10 ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド

Publications (3)

Publication Number Publication Date
JP2004509902A JP2004509902A (ja) 2004-04-02
JP2004509902A5 JP2004509902A5 (cg-RX-API-DMAC7.html) 2012-03-29
JP5016778B2 true JP5016778B2 (ja) 2012-09-05

Family

ID=8854579

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002529162A Expired - Fee Related JP5016778B2 (ja) 2000-09-22 2001-09-20 ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド
JP2012027377A Pending JP2012131809A (ja) 2000-09-22 2012-02-10 ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012027377A Pending JP2012131809A (ja) 2000-09-22 2012-02-10 ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド

Country Status (39)

Country Link
US (3) US6844329B2 (cg-RX-API-DMAC7.html)
EP (1) EP1322673B1 (cg-RX-API-DMAC7.html)
JP (2) JP5016778B2 (cg-RX-API-DMAC7.html)
KR (2) KR100891388B1 (cg-RX-API-DMAC7.html)
CN (1) CN1235914C (cg-RX-API-DMAC7.html)
AR (1) AR030774A1 (cg-RX-API-DMAC7.html)
AT (1) ATE374215T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001291960C1 (cg-RX-API-DMAC7.html)
BG (1) BG66191B1 (cg-RX-API-DMAC7.html)
BR (1) BR0114007A (cg-RX-API-DMAC7.html)
CA (1) CA2418815C (cg-RX-API-DMAC7.html)
CY (1) CY1108076T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ300856B6 (cg-RX-API-DMAC7.html)
DE (1) DE60130669T2 (cg-RX-API-DMAC7.html)
DK (1) DK1322673T3 (cg-RX-API-DMAC7.html)
EA (1) EA005133B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP034514A (cg-RX-API-DMAC7.html)
EE (1) EE05202B1 (cg-RX-API-DMAC7.html)
ES (1) ES2292625T3 (cg-RX-API-DMAC7.html)
FR (1) FR2814463B1 (cg-RX-API-DMAC7.html)
GE (1) GEP20053616B (cg-RX-API-DMAC7.html)
HR (1) HRP20030219B1 (cg-RX-API-DMAC7.html)
HU (2) HUP0303551A3 (cg-RX-API-DMAC7.html)
IL (2) IL154848A0 (cg-RX-API-DMAC7.html)
IS (1) IS2550B (cg-RX-API-DMAC7.html)
ME (2) ME00080B (cg-RX-API-DMAC7.html)
MX (1) MXPA03002483A (cg-RX-API-DMAC7.html)
NO (2) NO332905B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ524472A (cg-RX-API-DMAC7.html)
PE (1) PE20020471A1 (cg-RX-API-DMAC7.html)
PL (1) PL206727B1 (cg-RX-API-DMAC7.html)
PT (1) PT1322673E (cg-RX-API-DMAC7.html)
RS (1) RS50730B (cg-RX-API-DMAC7.html)
SI (1) SI1322673T1 (cg-RX-API-DMAC7.html)
SK (2) SK287218B6 (cg-RX-API-DMAC7.html)
TW (1) TWI308153B (cg-RX-API-DMAC7.html)
UA (1) UA79736C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002024754A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200301692B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
FR2874924B1 (fr) * 2004-09-09 2006-12-01 Sanofi Aventis Sa Hexadecasaccharides biotinyles, leur preparation et leur utilisation therapeutique
TWI403334B (zh) * 2004-12-23 2013-08-01 Merck Sharp & Dohme 包含生物素殘基之抗血栓雙重抑制劑
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
PL1991271T3 (pl) * 2005-10-10 2011-08-31 Merck Sharp & Dohme Podwójne inhibitory antykoagulacyjne -przeciwzakrzepowe zawierające znacznik biotynowy
ES2362011T3 (es) * 2005-10-10 2011-06-27 N.V. Organon Inhibidores duales antitrombóticos anticoagulantes que comprenden una marca de biotina.
CN1317035C (zh) * 2005-10-24 2007-05-23 天津大学 基于酰肼基的微粒表面多重生物功能因子组装方法
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
FR2912409B1 (fr) * 2007-02-14 2012-08-24 Sanofi Aventis Heparines de bas poids moleculaire comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine leur procede de preparation,leur utilisation
EP2233143A1 (en) 2009-03-24 2010-09-29 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
TW201006479A (en) * 2008-07-18 2010-02-16 Sanofi Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
EP2145624A1 (en) 2008-07-18 2010-01-20 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
FR2935386B1 (fr) * 2008-08-26 2010-09-10 Sanofi Aventis Nouveaux polysaccharides a activite antithrombotique comprenant une liaion covalente avec une chaine amine
WO2010029552A1 (en) * 2008-09-10 2010-03-18 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
AU2009335709A1 (en) 2008-12-19 2011-07-14 Supernus Pharmaceuticals, Inc. Method of treatment of aggression
FR2952935B1 (fr) 2009-11-20 2011-12-02 Sanofi Aventis Procede de preparation du n-biotinyl-6-aminocaproate de n succinimidyle
WO2011073408A2 (en) 2009-12-18 2011-06-23 Endotis Pharma Pharmaceutical oral dosage form containing a synthetic oligosaccharide
CZ302510B6 (cs) * 2010-03-29 2011-06-22 Univerzita Palackého v Olomouci Efektivní zpusob biotinylace sloucenin s karboxylovou skupinou pomocí syntézy na pevné fázi pro potreby afinitní chromatografie
CZ302669B6 (cs) * 2010-03-29 2011-08-24 Univerzita Palackého v Olomouci Efektivní zpusob biotinylace aminosloucenin pomocí syntézy na pevné fázi pro potreby afinitní chromatografie
ES2852899T3 (es) 2010-03-31 2021-09-14 Supernus Pharmaceuticals Inc Formulaciones estabilizadas de molindona
EP2614089A1 (fr) * 2010-09-10 2013-07-17 Sanofi-Aventis Polysaccharides biotinyles a activite antithrombotique et presentant une stabilite metabolique amelioree
FR2964660B1 (fr) * 2010-09-10 2012-09-28 Sanofi Aventis Nouveaux polysaccharides biotinyles a activite antithrombotique et presentant une stabilite metabolique amelioree
EP2484366A1 (en) 2011-02-07 2012-08-08 Sanofi Idrabiotaparinux for the treatment of pulmonary embolism and for the secondary prevention of venous thromboembolic events
ES2560467T3 (es) * 2011-06-17 2016-02-19 Carbomimetics Pentasacáridos sintéticos que tienen vida media corta y alta actividad
AU2013344920A1 (en) * 2012-11-13 2015-04-30 Supernus Pharmaceuticals, Inc. Method of treatment of aggression
WO2015195404A1 (en) 2014-06-20 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detection of an analyte by movement of tethered microparticles
WO2016205239A1 (en) 2015-06-15 2016-12-22 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Non-hormonal mammalian sperm decoy contraception based on the n-terminus of the zp2 protein
EP3529205B1 (en) 2016-10-21 2022-06-15 The United States of America, as represented by the Secretary, Department of Health and Human Services Molecular nanotags
CN108976318B (zh) * 2017-06-01 2021-03-30 首都医科大学 单-6-(生物素酰胺基)-6-脱氧-β-环糊精及其制备方法和应用
WO2019133727A1 (en) 2017-12-29 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Universal influenza virus probe set for enrichment of any influenza virus nucleic acid
JP2022540849A (ja) 2019-07-09 2022-09-20 オプティムヴィア、エルエルシー 抗凝固性多糖類の合成方法
CN114556685B (zh) * 2019-10-17 2024-04-02 株式会社自动网络技术研究所 布线模块
WO2022056078A1 (en) 2020-09-11 2022-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rnase h-assisted detection assay for rna (radar)
WO2024191684A1 (en) 2023-03-10 2024-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Detection of hepatitis c virus ribonucleic acid from whole blood using reverse transcription loop-mediated isothermal amplification

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960884A (en) * 1974-04-24 1976-06-01 Sergei Ivanovich Zavyalov Method of preparing racemic biotin
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides
IL102758A (en) * 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
FR2751334B1 (fr) * 1996-07-19 1998-10-16 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2773804B1 (fr) * 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
GB2335490B (en) * 1998-03-20 2003-05-14 Ortho Clinical Diagnostics An assay surface that permits an analyte releasiing step
AU8366398A (en) * 1998-07-07 2000-01-24 Department Of Radiation Oncology University Of Washington Trifunctional reagent for conjugation to a biomolecule
CA2305619C (en) 1998-07-31 2008-05-20 Seikagaku Corporation Novel glycosaminoglycan and pharmaceutical composition using the same as active ingredient
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine

Also Published As

Publication number Publication date
FR2814463A1 (fr) 2002-03-29
DE60130669D1 (de) 2007-11-08
HK1053316A1 (zh) 2003-10-17
CN1466594A (zh) 2004-01-07
US8318696B2 (en) 2012-11-27
PL206727B1 (pl) 2010-09-30
SK287218B6 (sk) 2010-03-08
FR2814463B1 (fr) 2002-11-15
MEP23608A (bs) 2010-06-10
US20040024197A1 (en) 2004-02-05
WO2002024754A1 (fr) 2002-03-28
HUP0303551A2 (hu) 2004-03-01
NO332905B1 (no) 2013-01-28
PT1322673E (pt) 2007-12-03
EE05202B1 (et) 2009-08-17
EE200300114A (et) 2005-02-15
IL154848A0 (en) 2003-10-31
DE60130669T2 (de) 2008-07-17
JP2004509902A (ja) 2004-04-02
UA79736C2 (uk) 2007-07-25
ME00080B (me) 2010-10-10
KR20030055269A (ko) 2003-07-02
HRP20030219B1 (hr) 2011-10-31
US7943595B2 (en) 2011-05-17
BR0114007A (pt) 2003-08-12
GEP20053616B (en) 2005-09-26
US20060160768A1 (en) 2006-07-20
MXPA03002483A (es) 2004-05-24
EP1322673B1 (fr) 2007-09-26
PL363368A1 (en) 2004-11-15
RS50730B (sr) 2010-08-31
AR030774A1 (es) 2003-09-03
US6844329B2 (en) 2005-01-18
NO20110401L (no) 2003-05-22
CN1235914C (zh) 2006-01-11
PE20020471A1 (es) 2002-06-01
SK3562003A3 (en) 2003-11-04
TWI308153B (en) 2009-04-01
SI1322673T1 (sl) 2008-02-29
HU1400034D0 (hu) 2004-03-01
CZ300856B6 (cs) 2009-08-26
CA2418815C (en) 2011-05-10
KR100891388B1 (ko) 2009-04-02
ECSP034514A (es) 2003-04-25
CA2418815A1 (en) 2002-03-28
EP1322673A1 (fr) 2003-07-02
NO20031295L (no) 2003-05-22
JP2012131809A (ja) 2012-07-12
HUP0303551A3 (en) 2004-03-29
BG107650A (bg) 2003-11-28
EA200300237A1 (ru) 2003-08-28
CZ2003814A3 (cs) 2003-06-18
AU2001291960C1 (en) 2009-10-08
IS6733A (is) 2003-02-28
ES2292625T3 (es) 2008-03-16
HRP20030219A2 (en) 2003-06-30
YU19703A (sh) 2006-05-25
ZA200301692B (en) 2004-03-01
EA005133B1 (ru) 2004-12-30
CY1108076T1 (el) 2014-02-12
BG66191B1 (bg) 2011-12-30
IS2550B (is) 2009-10-15
US20110144042A1 (en) 2011-06-16
NZ524472A (en) 2004-10-29
SK287054B6 (sk) 2009-10-07
IL154848A (en) 2010-11-30
NO20031295D0 (no) 2003-03-20
WO2002024754A8 (fr) 2003-07-03
AU2001291960B2 (en) 2007-03-01
DK1322673T3 (da) 2008-01-14
ATE374215T1 (de) 2007-10-15
KR20080049139A (ko) 2008-06-03
AU9196001A (en) 2002-04-02

Similar Documents

Publication Publication Date Title
JP5016778B2 (ja) ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド
US8703738B2 (en) Biotinylated hexadecasaccharides, preparation and use thereof
JP2012500884A (ja) 共有結合およびアミノ鎖を含む、抗血栓活性を有する多糖類
HK1113686B (en) Biotinylated hexadecasaccharides, preparation and use thereof
HK1053316B (en) Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111122

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120529

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120611

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150615

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees